within Pharmacolibrary.Drugs.ATC.G;

model G02CX05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.29,
    Cl             = 0.029833333333333333,
    adminDuration  = 600,
    adminMass      = 0.00175,
    adminCount     = 1,
    Vd             = 0.0253,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Bremelanotide is a melanocortin receptor agonist used for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It is administered subcutaneously and is currently approved for this indication in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy premenopausal women after a single subcutaneous dose.</p><h4>References</h4><ol><li>Danielle Mayer, Sarah E Lynch,Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder.,The Annals of pharmacotherapy,2020<a href='https://pubmed.ncbi.nlm.nih.gov/31893927/'>https://pubmed.ncbi.nlm.nih.gov/31893927/</a></li><li>Sarah Cipriani, Chiara Alfaroli, Elisa Maseroli, Linda Vignozzi,An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder.,Expert opinion on pharmacotherapy,2023<a href='https://pubmed.ncbi.nlm.nih.gov/36242769/'>https://pubmed.ncbi.nlm.nih.gov/36242769/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end G02CX05;
